Press Releases Press Releases Keyword Search Year None20202019201820172016201520142013 19 Nov '2020 XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail 21 Sep '2020 XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections 24 Aug '2020 XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization 17 Aug '2020 XBiotech Discovers COVID-19 Candidate Therapy 22 Jul '2020 XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy 14 Jul '2020 XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke 01 May '2020 XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy 14 Apr '2020 XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺) 03 Apr '2020 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients 19 Feb '2020 XBiotech Announces Final Results of Tender Offer Pagination Current page 1 Page 2 Next page next › Last page last »
Press Releases Keyword Search Year None20202019201820172016201520142013 19 Nov '2020 XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail 21 Sep '2020 XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections 24 Aug '2020 XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization 17 Aug '2020 XBiotech Discovers COVID-19 Candidate Therapy 22 Jul '2020 XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy 14 Jul '2020 XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke 01 May '2020 XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy 14 Apr '2020 XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺) 03 Apr '2020 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients 19 Feb '2020 XBiotech Announces Final Results of Tender Offer Pagination Current page 1 Page 2 Next page next › Last page last »
19 Nov '2020 XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
21 Sep '2020 XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
24 Aug '2020 XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
22 Jul '2020 XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy
14 Jul '2020 XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke
01 May '2020 XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy
03 Apr '2020 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
